A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia

Joseph Dao, Savreen Saran, Melody Wang, Christina Michael, Nhu Y. Phan, Alfredo Bellon

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ are often prescribed metformin and statins but its impact remains unsatisfactory. The use of aspirin (ASA) to decrease cardiovascular risk in the general population has been thoroughly investigated and clear guidelines are currently in place. Since adjuvant treatment with ASA could possibly decrease CVD risk and mortality in SCZ, we conducted a systematic review of the literature to determine the state of the current literature on this subject. Our systematic review points to gaps in the literature on CVD prevention in SCZ and illustrates an obvious need for further research. Although several studies have shown increased CVD risk in SCZ, to date, no research has been conducted on the utilization of CVD preventative treatment such as ASA for SCZ.

Original languageEnglish (US)
Article number368
JournalBrain Sciences
Issue number2
StatePublished - Feb 2023

All Science Journal Classification (ASJC) codes

  • General Neuroscience


Dive into the research topics of 'A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia'. Together they form a unique fingerprint.

Cite this